Long-term evaluation of immune status in leprosy patients undergoing multiple drug therapy.
A long-term survey of leprosy patients of all clinical types, starting at the time of diagnosis, was carried out to monitor clinical, bacteriological and immunological parameters at regular intervals during multiple drug therapy (MDT). The patients were assigned to two groups for treatment following WHO guidelines: paucibacillary (PB) and multibacillary (MB). Immunoglobulin levels, specific antibodies, skin-test responses to different soluble mycobacterial antigens (new tuberculins), and in vitro proliferative responses to mitogens and to antigens were measured during treatment, as were clinical changes, the bacterial index, and clinical improvement. No exact relations between disease activity and IgM antibody levels, both IgM immunoglobulin and specific IgM antibody to a species-specific antigen (ND-O-BSA), could be seen for MB patients. Changes in in vitro cell-mediated immunity and skin-test response seemed to be more directly related to the bacterial load and could reflect the improvement of bacteriological and clinical parameters during MDT.
Vu
T T
TT
Department of Immunology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.
Hoang
T L
TL
Nguyen
D Q
DQ
Ho
M L
ML
Nguyen
D H
DH
Le
T H
TH
Dang
D T
DT
Nguyen
Q A
QA
Le
T P
TP
Tran
H K
HK
D000372:Agglutination Tests; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology; D002991:Clofazimine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007111:Immunity, Cellular; D007075:Immunoglobulin M / Q000097:blood; D007136:Immunoglobulins / Q000097:blood*; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D008137:Longitudinal Studies; D008213:Lymphocyte Activation; D009166:Mycobacterium leprae / Q000276:immunology*; D012293:Rifampin / Q000627:therapeutic use; D012882:Skin Tests
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D007075:Immunoglobulin M; D007136:Immunoglobulins; D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin